{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:47:10Z","timestamp":1740134830720,"version":"3.37.3"},"reference-count":8,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,3,5]]},"DOI":"10.1182\/blood.2019004464","type":"journal-article","created":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T17:00:51Z","timestamp":1583427651000},"page":"704-706","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["The efficacy-toxicity conundrum: breaking the mold"],"prefix":"10.1182","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9462-6108","authenticated-orcid":false,"given":"Louis F.","family":"Diehl","sequence":"first","affiliation":[{"name":"Duke University Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"10","key":"2020030512004661200_B1","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood.2019003127","article-title":"Brentuximab vedotin with chemotherapy for stage III\/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study","volume":"135","author":"Straus","year":"2020","journal-title":"Blood"},{"issue":"27","key":"2020030512004661200_B2","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2008.19.8820","article-title":"Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin\u2019s lymphoma: 10 years of follow-up of the GHSG HD9 study","volume":"27","author":"Engert","year":"2009","journal-title":"J Clin Oncol"},{"issue":"24","key":"2020030512004661200_B3","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin\u2019s disease [published correction appears in N Engl J Med. 2005;353(7):744]","volume":"348","author":"Diehl","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"2020030512004661200_B4","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/bjh.12715","article-title":"The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma","volume":"165","author":"Oki","year":"2014","journal-title":"Br J Haematol"},{"issue":"25","key":"2020030512004661200_B5","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"2020030512004661200_B6","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S1470-2045(17)30103-1","article-title":"Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin\u2019s lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group","volume":"18","author":"Borchmann","year":"2017","journal-title":"Lancet Oncol"},{"issue":"5","key":"2020030512004661200_B7","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2017.75.2543","article-title":"Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography\/computed tomography scan after two ABVD cycles: long-term results of the GITIL\/FIL HD 0607 trial","volume":"36","author":"Gallamini","year":"2018","journal-title":"J Clin Oncol"},{"issue":"15","key":"2020030512004661200_B8","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1182\/blood.2019000719","article-title":"Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III\/IV Hodgkin lymphoma","volume":"134","author":"Stephens","year":"2019","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/10\/704\/1717874\/bloodbld2019004464c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/10\/704\/1717874\/bloodbld2019004464c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T18:58:26Z","timestamp":1614711506000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/135\/10\/704\/452587\/The-efficacytoxicity-conundrum-breaking-the-mold"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,5]]},"references-count":8,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,3,5]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019004464","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"type":"print","value":"0006-4971"},{"type":"electronic","value":"1528-0020"}],"subject":[],"published":{"date-parts":[[2020,3,5]]}}}